Clinical Trial Update: A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating KarXT plus KarX-EC for treating irritability in children and adolescents with autism is currently not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autism Spectrum Disorder

Drugs mentioned

• KarX-EC
• KarXT (xanomeline-trospium)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Irritability Associated With Autism Spectrum Disorder | Phase 3 | Status: NOT_YET_RECRUITING